US Patent

US8877933 — Thermodynamically stable form of a tosylate salt

Method of Use · Assigned to Bayer Intellectual Property GmbH · Expires 2027-12-24 · 2y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a thermodynamically stable form of the tosylate salt of a specific chemical compound, used in medicaments.

USPTO Abstract

The present invention relates to a novel form, thermodynamically stable at room temperature, of the tosylate salt of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide, to processes for its preparation, to medicaments comprising it and to its use in the control of disorders.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1624 sorafenib-tosylate

Patent Metadata

Patent number
US8877933
Jurisdiction
US
Classification
Method of Use
Expires
2027-12-24
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Bayer Intellectual Property GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.